FDA Authorizes Bivalent COVID-19 Booster for Young Children

The FDA amended the emergency use authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine to provide for a single booster dose of the vaccine in children 6 months through 4 years of age at least two months after completion of primary vaccination with three doses of the monovalent (single strain) Pfizer-BioNTech COVID-19 Vaccine. Read the FDA announcement.